Impacto de la resistencia microbiana a antibióticos a causa de la pandemia del covid-19
DOI:
https://doi.org/10.23857/dc.v9i1.3126Palabras clave:
COVID-19; Microbial resistance; Antibiotics; Antibiotic resistance; Increasing resistance to antibiotics; Current antibiotic resistance.Resumen
Este articulo trata sobre la resistencia desarrollada por microorganismos a los antibióticos y el impacto que ha causado la pandemia del COVID-19 en el aumento de esta problemática a nivel mundial. A lo largo de los años la resistencia microbiana ha ido en aumento, debido al uso desmedido de antibióticos, además del uso antibiótico automedicado por la población en general, y sobre todo a raíz de la pandemia del SARS-CoV-2 ya que durante el inicio del brote, en diferentes países se usó un esquema empírico de antibióticos para intentar frenar el avance de la enfermedad como tal en el organismo, sin embargo muchos de estos esquemas carecían completamente de validez, ya que al tratarse de un virus, el uso antibiótico era innecesario en muchos de los casos, salvo aquellos pacientes que presentaron una infección viral y bacteriana debido a microorganismos nosocomiales provocados por estadías prolongadas en centros hospitalarios. Mientras que gran parte de la población procuro usar una amplia gama de métodos para evitar contraer la infección del virus, usando desde antibióticos hasta antiparasitarios.
Citas
Choudhury S, Medina-lara A, Smith R. Antimicrobial resistance and the COVID-19 pandemic. Bull World Heal Organ 2022; 2022;2019:2019–20.
Mendelson M. BSAC Vanguard Series: Inequality and antibiotic resistance. J Antimicrob Chemother. 2022;77(2):277–8.
Covid- E. El COVID-19 hace retroceder el progreso en la lucha contra la resistencia a los antimicrobianos en los EE . UU . 2022;1–3.
Pan American Health Organization. El impacto de la COVID-19 en la resistencia antimicrobiana - OPS/OMS | Organización Panamericana de la Salud. 2021;19:1–8. Available from: https://www.paho.org/es/noticias/17-11-2021-impacto-covid-19-resistencia-antimicrobiana
Usman M, Farooq M, Hanna K. Environmental side effects of the injudicious use of antimicrobials in the era of COVID-19. Sci Total Environ [Internet]. 2020;745:141053. Available from: https://doi.org/10.1016/j.scitotenv.2020.141053
Pérez de la Lastra JM, Anand U, González-Acosta S, López MR, Dey A, Bontempi E, et al. Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides? Front Immunol. 2022;13(June):1–13.
Shomuyiwa DO, Lucero-Prisno DE, Manirambona E, Suleman MH, Rayan RA, Huang J, et al. Curbing antimicrobial resistance in post-COVID Africa: Challenges, actions and recommendations. Heal Sci Reports. 2022;5(5).
Kamara IF, Kumar AMV, Maruta A, Fofanah BD, Njuguna CK, Shongwe S, et al. Antibiotic Use in Suspected and Confirmed COVID-19 Patients Admitted to Health Facilities in Sierra Leone in 2020–2021: Practice Does Not Follow Policy. Int J Environ Res Public Health. 2022;19(7).
Sulayyim HJ Al, Ismail R, Hamid A Al, Ghafar NA. Antibiotic Resistance during COVID-19: A Systematic Review. Int J Environ Res Public Health. 2022;19(19).
HIRIS. Informe sobre Resistencia Antimicrobiana 2021. Hiris [Internet]. 2021; Available from: https://seq.es/wp-content/uploads/2021/10/Informe-RAM-2021.pdf
Boyanova L, Markovska R, Mitov I, Gergova R. Non-viral infections and antimicrobial resistance in the time of COVID-19: what to expect? Expert Rev Clin Pharmacol [Internet]. 2022;15(8):907–9. Available from: https://doi.org/10.1080/17512433.2022.2108403
Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.
Mabrouk DM. Antimicrobial peptides: features, applications and the potential use against covid-19. Mol Biol Rep [Internet]. 2022;49(10):10039–50. Available from: https://doi.org/10.1007/s11033-022-07572-1
La APOR. PANDEMIA DE COVID-19. Organ Panam la salud. 2021;16.
Alós J-I. Resistencia bacteriana a los antibióticos: una crisis global. Enferm Infecc Microbiol Clin. 2015;33(10):692–9.
1Russo A, Gavaruzzi F, Ceccarelli G, Borrazzo C, Oliva A, Alessandri F, et al. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection [Internet]. 2022;50(1):83–92. Available from: https://doi.org/10.1007/s15010-021-01643-4
Rizvi SG, Ahammad SZ. COVID-19 and antimicrobial resistance: A cross-study. Sci Total Environ [Internet]. 2022;807:150873. Available from: https://doi.org/10.1016/j.scitotenv.2021.150873
Cappelli F, Longoni O, Rigato J, Rusconi M, Sala A, Fochi I, et al. Suspect screening of wastewaters to trace anti-COVID-19 drugs: Potential adverse effects on aquatic environment. Sci Total Environ [Internet]. 2022;824:153756. Available from: https://doi.org/10.1016/j.scitotenv.2022.153756
Seethalakshmi PS, Charity OJ, Giakoumis T, Kiran GS, Sriskandan S, Voulvoulis N, et al. Delineating the impact of COVID-19 on antimicrobial resistance: An Indian perspective. Sci Total Environ [Internet]. 2022;818:151702. Available from: https://doi.org/10.1016/j.scitotenv.2021.151702
Sharma S, Barman P, Joshi S, Preet S, Saini A. Multidrug resistance crisis during COVID-19 pandemic: Role of anti-microbial peptides as next-generation therapeutics. Colloids Surfaces B Biointerfaces [Internet]. 2022;211(August 2021):112303. Available from: https://doi.org/10.1016/j.colsurfb.2021.112303
Zhou SYD, Lin C, Yang K, Yang LY, Yang XR, Huang FY, et al. Discarded masks as hotspots of antibiotic resistance genes during COVID-19 pandemic. J Hazard Mater [Internet]. 2022;425(September 2021):127774. Available from: https://doi.org/10.1016/j.jhazmat.2021.127774
Kang Y, Chen S, Chen Y, Tian L, Wu Q, Zheng M, et al. Alterations of fecal antibiotic resistome in COVID-19 patients after empirical antibiotic exposure. Int J Hyg Environ Health [Internet]. 2022;240(November 2021):113882. Available from: https://doi.org/10.1016/j.ijheh.2021.113882
Floridia M, Giuliano M, Monaco M, Palmieri L, Lo Noce C, Palamara AT, et al. Microbiologically confirmed infections and antibiotic-resistance in a national surveillance study of hospitalised patients who died with COVID-19, Italy 2020–2021. Antimicrob Resist Infect Control. 2022;11(1):1–9.
El-Ansary A, Balto H, Al-Hadlaq SM, Auda SH, Marraiki N. Control of antibiotic resistance and superinfections as a strategy to manage COVID-19 deaths [Internet]. Data Science for COVID-19: Volume 2: Societal and Medical Perspectives. Elsevier Inc.; 2021. 507–530 p. Available from: http://dx.doi.org/10.1016/B978-0-323-90769-9.00016-5
Singulani JL, Silva DL, Lima CM, Magalhães VCR, Baltazar LM, Peres NTA, et al. The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria. Brazilian J Microbiol [Internet]. 2022;1925–35. Available from: https://doi.org/10.1007/s42770-022-00818-x
Meschiari M, Onorato L, Bacca E, Orlando G, Menozzi M, Franceschini E, et al. Long-Term Impact of the COVID-19 Pandemic on In-Hospital Antibiotic Consumption and Antibiotic Resistance: A Time Series Analysis (2015–2021). Antibiotics. 2022;11(6).
Rizvi A, Saeed MU, Nadeem A, Yaqoob A, Rabaan AA, Bakhrebah MA, et al. Evaluation of Bi-Lateral Co-Infections and Antibiotic Resistance Rates among COVID-19 Patients in Lahore, Pakistan. Med. 2022;58(7).
Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect [Internet]. 2021;27(4):520–31. Available from: https://doi.org/10.1016/j.cmi.2020.12.018
Murillo-Zamora E, Trujillo X, Huerta M, Mendoza-Cano O, Guzmán-Esquivel J, Guzmán-Solórzano JA, et al. Empirical Antibiotic Prescribing in Adult COVID-19 Inpatients over Two Years in Mexico. Antibiotics. 2022;11(6):1–7.
Despotovi? A, Bara? A, Cucani? T, Cucani? K, Stevanovi? G. Antibiotic (Mis)Use in COVID-19 Patients before and after Admission to a Tertiary Hospital in Serbia. Antibiotics. 2022;11(7):4–11.
Mondal UK, Haque T, Biswas MAAJ, Satter SM, Islam MS, Alam Z, et al. Antibiotic Prescribing Practices for Treating COVID-19 Patients in Bangladesh. Antibiotics. 2022;11(10):1–14.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Frank Sebastián Domínguez Espín , Josué Pablo Chicaiza Abad , María Fernanda Sánchez Altamirano , Elvia Jeanette Muñoz Sanizaca , Cynthia Michelle Tixilema Arias
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Authors retain copyright and guarantee the Journal the right to be the first publication of the work. These are covered by a Creative Commons (CC BY-NC-ND 4.0) license that allows others to share the work with an acknowledgment of the work authorship and the initial publication in this journal.
